World
FDA pauses Regenxbio Hunter syndrome gene therapy trial The FDA put a hold on a Regenxbio gene therapy trial again after new safety concerns emerged.
The FDA put a hold on a Regenxbio gene therapy trial again after new safety concerns emerged.
Dr. Kai NakamuraChief Science CorrespondentPublished Aug 24, 2026 at 4:07 PM EDT · 1 min read
FDA pauses Regenxbio Hunter syndrome gene therapy trial The FDA put a hold on a Regenxbio gene therapy trial again after new safety concerns emerged. The FDA put a hold on a Regenxbio gene therapy trial again after new safety concerns emerged.
Continue reading
Latest →Corrections, sourcing and article labels are part of the publication record. See our editorial standards.